Clinical Trial Update: Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of selumetinib in recurrent or persistent endometrial cancer has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Adenosquamous Carcinoma
• Endometrial Clear Cell Adenocarcinoma
• Uterine Corpus Carcinoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-20